Diabetes Education News

People who delayed diabetes through diet and exercise for at least 4 years after their prediabetes diagnosis had a lower risk for death and other adverse outcomes vs. those who were diagnosed with diabetes during that time, a study showed.

Combined SGLT2 inhibitor and GLP-1 receptor agonist therapy could provide additional cardiovascular and renal benefits for adults with type 2 diabetes, according to data from a meta-analysis published in The Lancet Diabetes & Endocrinology.

The FDA declined to approve once-weekly basal insulin icodec for the treatment of diabetes and is requesting more information from Novo Nordisk, according to a company press release.

Circulating levels of some microRNA species may predict response to diabetes treatment and changes in beta-cell function among children and adolescents with type 2 diabetes, according to findings from the TODAY study.

More than one in five adults in the U.S. with type 1 diabetes also have chronic kidney disease, according to findings from a brief report published in Diabetes Care.

Adults with overweight or obesity lost more weight with the GIP/GLP-1 dual agonist tirzepatide than the GLP-1 receptor agonist semaglutide, according to findings published in JAMA Internal Medicine.

People with type 2 diabetes who use a GLP-1 receptor agonist have a lower risk for 10 types of obesity-associated cancer compared with those who use insulin, according to data published in JAMA Network Open.

Adults with diabetes or obesity using semaglutide may have an increased risk for nonarteritic anterior ischemic optic neuropathy, a common form of optic neuropathy, according to data published in JAMA Ophthalmology.

Women with type 2 diabetes diagnosed with hypertension at younger than age 50 years have an increased risk for cardiovascular disease and could benefit from intensive antihypertension therapy according to data published in Diabetes Care.

AI in diabetes care is becoming more popular with various potential benefits for patients and clinicians as well as important challenges to keep in mind, according to a conversation between two diabetes experts.